Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes:...

por Mohan, Viswanathan, Schmider, Wolfgang, Singh, Kiran P., Rotthaeuser, Baerbel, Mukherjee, Bhaswati, Aravind, S. R.
Publicado 2022

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump

por Thrasher, James, Surks, Howard, Nowotny, Irene, Pierre, Suzanne, Rotthaeuser, Baerbel, Wernicke-Panten, Karin, Garg, Satish
Publicado 2018

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M):...

por Aravind, S. R., Singh, Kiran P., Mogylnytska, Liliia, Zalevskaya, Alsu G., Matyjaszek-Matuszek, Beata, Wernicke-Panten, Karin, Nguyên-Pascal, My-Liên, Pierre, Suzanne, Rotthaeuser, Baerbel, Kramer, Daniel, Mukherjee, Bhaswati
Publicado 2022

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMEL...

por Aravind, S. R., Singh, Kiran P., Aquitania, Grace, Mogylnytska, Liliia, Zalevskaya, Alsu G., Matyjaszek-Matuszek, Beata, Wernicke-Panten, Karin, Nguyên-Pascal, My-Liên, Pierre, Suzanne, Rotthaeuser, Baerbel, Kramer, Daniel, Mukherjee, Bhaswati
Publicado 2022